Literature DB >> 15215226

Influence of penicillin resistance on outcome in adult patients with invasive pneumococcal pneumonia: is penicillin useful against intermediately resistant strains?

Vicenç Falcó1, Benito Almirante, Queralt Jordano, Laura Calonge, Oscar del Valle, Carles Pigrau, Ana María Planes, Joan Gavaldà, Albert Pahissa.   

Abstract

OBJECTIVES: To compare outcome between patients with pneumonia due to penicillin-susceptible S. pneumoniae and patients with pneumonia due to penicillin intermediately resistant strains and to study the outcome of patients with pneumococcal pneumonia caused by strains with MICs of 0.12-1 mg/L treated empirically during the first 48 h with beta-lactam antibiotics.
MATERIALS AND METHODS: We studied 247 adult patients with invasive pneumococcal pneumonia occurring from 1997 to 2001. The following data were recorded from each patient: socio-demographic characteristics, underlying diseases, clinical presentation, initial severity of pneumonia, initial and subsequent antimicrobial therapy, in-hospital complications, hospital mortality and length of hospital stay. Multivariate analysis was done to identify variables associated with the development of pneumonia caused by a non-susceptible strain.
RESULTS: The overall presence of penicillin non-susceptibility was 26.7%; no strain had an MIC >2 mg/L. Overall mortality was 23.5% in patients with pneumonia caused by intermediately resistant pneumococci and 12.7% in those with pneumonia caused by susceptible strains (P=0.075). Mortality during the first 7 days of admission, considered to be pneumonia-related deaths (13.7% versus 9.9%; P=0.448) was similar in both groups. The multivariate analysis showed that serotype 14 (OR, 140.18; 95% CI, 16.95-1159.20), serotype 19 (OR, 7.53; 95% CI, 1.98-28.7), haematological malignancy or splenectomy (OR, 4.46; 95% CI, 1.5-13.23) and HIV infection (OR, 4.54; 95% CI, 1.54-13.44) were the only independent factors associated with pneumonia caused by penicillin intermediately resistant pneumococci. In patients with strains having MICs of 0.1-1 mg/L, overall mortality was similar in the group of penicillin-treated patients (22.2%) to those treated with broad-spectrum beta-lactams (23.5%).
CONCLUSIONS: There is a non-significant trend to higher mortality in patients with pneumococcal pneumonia caused by intermediately resistant strains; however, they do not have a poorer outcome when they are treated with amoxicillin.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15215226     DOI: 10.1093/jac/dkh338

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  10 in total

1.  Impact of penicillin nonsusceptibility on clinical outcomes of patients with nonmeningeal Streptococcus pneumoniae bacteremia in the era of the 2008 clinical and laboratory standards institute penicillin breakpoints.

Authors:  Seong-Ho Choi; Jin-Won Chung; Heungsup Sung; Mi-Na Kim; Sung-Han Kim; Sang-Oh Lee; Yang Soo Kim; Jun Hee Woo; Sang-Ho Choi
Journal:  Antimicrob Agents Chemother       Date:  2012-06-11       Impact factor: 5.191

2.  Guidelines for the management of adult lower respiratory tract infections--full version.

Authors:  M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij
Journal:  Clin Microbiol Infect       Date:  2011-11       Impact factor: 8.067

Review 3.  [Sense and nonsense in antibiotic therapy for respiratory tract infections].

Authors:  W Domej; E Flögel; G P Tilz; U Demel
Journal:  Internist (Berl)       Date:  2005-07       Impact factor: 0.743

Review 4.  Setting and revising antibacterial susceptibility breakpoints.

Authors:  John Turnidge; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2007-07       Impact factor: 26.132

5.  Clinical outcomes of bacteremic pneumococcal infections in an area with high resistance.

Authors:  P L Ho; T L Que; T K Ng; S S Chiu; R W H Yung; K W T Tsang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-05       Impact factor: 3.267

Review 6.  Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options.

Authors:  Françoise Van Bambeke; René R Reinert; Peter C Appelbaum; Paul M Tulkens; Willy E Peetermans
Journal:  Drugs       Date:  2007       Impact factor: 9.546

7.  Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumonia.

Authors:  Diego J Maselli; Juan F Fernandez; Christine Y Whong; Kelly Echevarria; Anoop M Nambiar; Antonio Anzueto; Marcos I Restrepo
Journal:  Infect Drug Resist       Date:  2012-02-01       Impact factor: 4.003

8.  COMPARATIVE EFFICACY AND SAFETY OF CEFIXIME AND CIPROFLOXACIN IN THE MANAGEMENT OF ADULTS WITH COMMUNITY-ACQUIRED PNEUMONIA IN IBADAN, NIGERIA.

Authors:  O M Ige; A O Okesola
Journal:  Ann Ib Postgrad Med       Date:  2015-12

9.  Efficacy and safety of oral gemifloxacin for the empirical treatment of pneumonia.

Authors:  Vindu Amitabh; Anish Singhal; Sudhir Kumar; Narmada Patel; Yasir S Rizvi; Pankaj Mishra
Journal:  Lung India       Date:  2012-07

10.  Drug-resistance in Streptococcus pneumoniae isolates among Spanish middle aged and older adults with community-acquired pneumonia.

Authors:  Angel Vila-Corcoles; Ferran Bejarano-Romero; Elisabeth Salsench; Olga Ochoa-Gondar; Cinta de Diego; Frederic Gomez-Bertomeu; Xavier Raga-Luria; Xavier Cliville-Guasch; Victoria Arija
Journal:  BMC Infect Dis       Date:  2009-03-25       Impact factor: 3.090

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.